Premature Ejaculation Treatment Market to Record a CAGR of 9.06%, High Efficacy of Off-label Drugs to Boost Market Growth – Technavio – QNT Press Release

[ad_1]

NEW YORK, Sept. 9, 2022 /PRNewswire/ — The “Premature Ejaculation Treatment Market by Route of Administration (Oral and Topical), Drug Class (SSRIs, PDE5 inhibitors, Amide Anesthetics, and Others), and Geography (North America, Europe, Asiaand Rest of World (ROW)) – Forecast and Analysis 2022-2026″ report has been added to Technavio’s offering. The potential growth difference for the premature ejaculation treatment market size between 2021 and 2026 is USD 1.26bn. To get the exact CAGR and the YOY growth rate, Request a FREE PDF Sample Report

• Market Driver: The high efficacy of off-label drugs is driving the growth of the market. The use of off-label drugs of different drug classes, including SSRIs and PDE5 inhibitors, has increased owing to their effectiveness in the treatment of premature ejaculation. In addition, according to some clinical studies, combining PDE5 inhibitors with SSRIs leads to better results in the treatment of premature ejaculation than using SSRIs alone. Thus, the high efficacy of these drugs is increasing their demand among end-users, which is contributing to the growth of the global premature ejaculation treatment market.
• Market Challenge: The availability of alternative treatment options is challenging the growth of the market. The rising number of premature ejaculation cases across the world has led to a growth in the number of alternative treatment methods for the disease. Some of the alternate treatment methods include homeopathy, psychotherapy, yoga, counseling, and herbal therapy. Some of these treatment options are believed to have little or no side effects when compared to mainstream premature ejaculation treatment drugs. Thus, the rising popularity of alternative premature ejaculation treatment options has hindered the growth of pharmacological therapies, which is posing a to market growth.

Technavio offers additional key drivers, trends, and challenges that will impact the growth of the market. Read our FREE PDF Sample Report right now!

By route of administration, the oral segment will be the largest contributor to market growth during the forecast period. These drugs are available in different forms, such as capsules, tablets, and liquids. The growth of this segment is attributed to factors such as the popularity and high preference for oral medication as the first line of treatment for premature ejaculation.

By geography, North America will be the leading region with 39% of the market’s growth during the forecast period. The US is the key country for the premature ejaculation treatment market in North America. The growth of this region is attributed to factors such as a significant increase in the number of premature ejaculation cases. However, market growth in this region will be slower than the growth of the market in other regions.

View our FREE PDF sample report for additional insights into the contribution of all the segments and regional opportunities in the report.

• A. Menarini Industrie Farmaceutiche Riunite Srl
• Absorption Pharmaceuticals LLC
• Alembic Pharmaceuticals Inc.
• Amneal Pharmaceuticals Inc.
• ANI Pharmaceuticals Inc.
• Aytu BioPharma Inc.
• Bayer AG
• Cipla Ltd.
• Eli Lilly and Co.
• Endurance RP Ltd.
• GlaxoSmithKline Plc
• Johnson and Johnson
• Lupin Ltd.
• NeuroHealing Pharmaceuticals Inc.
• Novitium Pharma
• Pfizer Inc.
• Plethora Solutions Ltd.
• Sandoz International GmbH
• Solco Healthcare
• Teva Pharmaceutical Industries Ltd.

Want your report customized? Speak to an analyst and personalize your report according to your needs

Testosterone Replacement Therapy Market by, Product, and Geography – Forecast and Analysis 2022-2026

Sexual Enhancement Supplements Market by Product and Geography – Forecast and Analysis 2022-2026

Full story available on Benzinga.com

[ad_2]

Source link